Abstract
Backgrounds: The aim of this study is to demonstrate HANP administration combined with acute revascularization prevent LV remodeling independent of myocardial salvage. Methods: Consecutive 44 patients with acute anteroseptal myocardial infarction were randomly assigned to either continuous infusion of HANP at a dose of 0.025 microgram/kg/min for 3 days, or control. Myocardial salvage, infarct size, and LV volume was assessed by 99mTc-tetrofosmin imaging. Results: No differences in patients backgrounds were observed. HANP suppressed LVEDVI increase in comparison with placebo (HANP:3.2 ± 16.8 control:16.0 ± 23.4 p < 0.05) with no difference in salvage index(HANP:55.6 ± 24.9% control:55.5 ± 34.1%). The relationship between the infarct size and delta-LVEDVI were shown in the figure. Conclusion: This study clearly demonstrate that HANP can suppress LV volume expansion despite no difference of infarct size. [Display omitted]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
